More than half of women treated with chemotherapy for localized breast cancer reported persistent amenorrhea at year 4 after diagnosis, according to a French study.
Differences in outcomes and quality of life across commonly used treatments for endocrine-refractory and triple-negative metastatic breast cancer were "razor-thin," leaving cost as a key factor.
Advocates who have been calling for reforms in the accelerated approvals process are concerned that Congress may avoid this issue while finalizing a major FDA law.
The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.